Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 28, 2008

View Archived Issues

Nissan Chemical patents novel antithrombocytopenic compounds

New therapeutic agents for thrombotic disorders described in recent patent literature

Novartis reports 2007 results

Regulatory T-cell loss of function triggers type 1 diabetes in mice

Epix achieves milestone in collaboration with Cystic Fibrosis Foundation

FDA Advisory Committee votes favorably for Entereg in postoperative ileus

New treatment options for inflammatory and allergic conditions disclosed in Icos patent

Nabi Biopharmaceuticals initiates new strategic alternatives process

Patient enrollment begins for NIH funded SFP clinical study

Bayer extends its liver cancer product portfolio in Japan

CombinatoRx provides update on 2008 goals

Combination of quetiapine and a mood stabilizer more effective in preventing mood episodes

Data Safety Monitoring Board reviews phase III defibrotide trial

First and only antiinflammatory pain relief patch available in the U.S.

GSK allies with institutions in tuberculosis and malaria drug discovery programs

GSK/MRC to identify new therapeutic targets from genetic association studies

M.D. Anderson and AstraZeneca form cancer-related neuropathic pain alliance

Protherics initiates OncoGel phase IIb study in esophageal cancer

BioCryst updates clinical development plan for intramuscular peramivir

Novartis reports positive primary endpoint from the FIRST-STEP study of Stalevo

Cangene's recombinant human growth hormone approved by the FDA

Kipres approved for additional indication of allergic rhinitis

Promising preclinical results for FGL in stress-induced cognitive deficits

Kirin Pharma launches Regpara tablets for secondary hyperparathyroidism

EMEA recommends approval of novel oral anticoagulant, Pradaxa

Clexane, sanofi-aventis' anticoagulant, is approved for marketing in Japan

Antibacterial Gracevit receives manufacturing and marketing approval in Japan

First launch of Optaflu in Germany

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...